The Global Pharmaceutical Glass Tubing Market, valued at USD 9.56 Billion in 2025, is projected to exhibit a CAGR of 7.3%, reaching USD 15.65 Billion by 2032.
Market growth is primarily driven by the increasing demand for injectable drugs, vaccines, and biologics that require high-quality primary packaging such as vials, ampoules, cartridges, and prefilled syringes. The shift toward biologics and biosimilars, along with stringent regulatory standards for drug packaging safety and integrity, is accelerating the adoption of Type I borosilicate glass tubing.
Rising investments by pharmaceutical companies and contract manufacturing organizations (CMOs) in expanding production capacities are further supporting the market expansion. In addition, advancements in glass tubing technologies, such as improved chemical resistance, reduced extractables, and enhanced manufacturing precision, are strengthening reliability and performance. Growing healthcare infrastructure in emerging economies, coupled with increasing government support for vaccine and biologics production, is expected to create significant opportunities for the market over the forecast period.
Market Takeaways
Global Pharmaceutical Glass Tubing Market Report Coverage
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/global-pharmaceutical-glass-tubing-market
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 9.56 Billion |
|
Estimated Value by 2032 |
USD 15.65 Billion |
|
Growth Rate |
Poised to exhibit a CAGR of 7.3% |
|
Historical Data |
2020-2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Trends |
|
|
Opportunities |
|
|
Restraints & Challenges |
|
Market Dynamics
The global pharmaceutical glass tubing market is witnessing steady growth, primarily fueled by the rising demand for injectable drugs, vaccines, and biologics that require reliable primary packaging formats such as vials, ampoules, cartridges, and prefilled syringes. The increasing prevalence of chronic diseases, along with the expanding use of biologics and biosimilars, is driving the need for borosilicate and neutral glass tubing due to their superior chemical resistance and ability to maintain drug stability.
A key growth driver is the rapid expansion of global pharmaceutical manufacturing capacity, particularly among contract manufacturing organizations (CMOs) and vaccine producers, which has created sustained demand for high-quality glass tubing. Advances in glass production—such as improved chemical durability, reduced extractables, and tighter dimensional control—are further enhancing product integrity and safety. At the same time, stringent regulatory requirements on container closure integrity (CCI) and pharmacopeia compliance are accelerating the adoption of premium Type I borosilicate tubing.
Recent industry investments reflect this trend. In March 2023, SCHOTT announced a USD 80.3 million (€75 million) expansion of its pharma glass tubing facility in Jambusar, Gujarat, India, aimed at doubling production capacity for borosilicate tubing used in vials, ampoules, and syringes. Similarly, several leading suppliers have invested in furnace upgrades, plant automation, and large-scale capacity expansion to meet heightened demand following COVID-19 vaccine rollouts. Strategic collaborations between glass tubing manufacturers and pharmaceutical companies are increasingly shaping supply chain resilience and ensuring uninterrupted availability of critical packaging materials.
On the downside, the market faces cost pressures from high energy consumption and raw material prices, which significantly impact production economics. Growing competition from advanced polymer-based packaging alternatives for niche applications also presents a challenge. Moreover, supply chain disruptions and the capital-intensive nature of glass tubing manufacturing remain barriers for new entrants.
Despite these hurdles, the long-term outlook remains positive. Strong growth prospects are supported by rising demand from emerging economies, greater penetration of biologics and specialty medicines, and ongoing innovations in glass composition and forming technologies. These factors are expected to unlock substantial opportunities for manufacturers over the forecast period.
Market Trends
Advanced Type I borosilicate glass tubing is being developed to enhance drug stability, safety, and sustainability. These next‑generation formulations offer higher purity and chemical resistance to minimize leachables/extractables, improved mechanical strength to reduce breakage during handling, and sustainability benefits such as lower carbon footprint and recyclability, addressing the evolving needs of complex pharmaceuticals.
In October 2023, SCHOTT launched a next‑generation Type I borosilicate glass tubing designed to address the evolving needs of the pharmaceutical industry. The product and associated services aim to support three major trends: the increasing complexity of pharmaceuticals, sustainability initiatives, and the integration of digital solutions.
Pharmaceutical glass manufacturers are increasingly focusing on environmentally friendly production and localised supply chains. Initiatives include using recycled glass, energy-efficient manufacturing, and lower-carbon transport, while locating production closer to demand centers. These efforts reduce environmental impact, enhance supply reliability, and support faster delivery for pharmaceutical customers.
In August 2025, SCHOTT commenced the construction of an electric melting tank in Mitterteich, Germany, powered entirely by 100% green electricity. This initiative aims to reduce carbon emissions by 50% during the production of pharmaceutical glass tubing, aligning with the company's commitment to sustainability.
Market Opportunities
The rapid growth of biologics, vaccines, and gene/cell therapies creates demand for high-purity, chemically resistant glass tubing. Manufacturers can offer specialized Type I borosilicate glass and pre-sterilized “ready-to-fill” tubing solutions to support these sensitive drugs.
In June 2023, Corning Incorporated and SGD Pharma announced a joint venture to open a new glass tubing facility in Telangana, India. This facility aims to produce high-quality Type I borosilicate glass tubing, a critical material for injectable drug packaging, diagnostics, and biologics. The collaboration combines Corning’s Velocity Vial technology with SGD Pharma’s vial-converting expertise to enhance vial quality and improve filling-line productivity.
With global supply chain disruptions becoming increasingly frequent, pharmaceutical glass manufacturers are exploring opportunities to establish local production facilities in regions such as Asia Pacific, Latin America, and other emerging markets. By producing high-quality glass tubing closer to end users, companies can significantly reduce lead times, lower logistics and transportation costs, and enhance responsiveness to market demand. This localized approach also mitigates risks associated with import dependencies and enables manufacturers to capture greater market share from competitors that rely primarily on centralized, long-distance supply chains.
Analyst view
Key Developments
Competitive Landscape
Global Pharmaceutical Glass Tubing Market Segmentation
Regional Insights
Related Reports :